Swedish lung cancer radiation study group: the prognostic value of anaemia, thrombocytosis and leukocytosis at time of diagnosis in patients with non-small cell lung cancer
(2012) In Medical Oncology 29(5). p.3176-3182- Abstract
- There is a need to improve the prognostic and predictive indicators in non-small cell lung cancer (NSCLC). At present, the main focus is on genetic predictive markers while the prognostic value of the standard blood variables related to haematopoiesis has been subjected to relatively limited attention. To study the prognostic potential of haemoglobin (Hgb), platelet (Plt) and white blood cell (WBC) levels at time of diagnosis in NSCLC patients, 835 NSCLC patients, stage I-IV, who received radiotherapy with curative intention (> 50 Gy), were included in the study. WBC, Plt, Hgb, gender, age at diagnosis, stage, surgery and first-line chemotherapy were studied in relation to overall survival. For patients with Hgb < 110 g/L and Hgb a... (More)
- There is a need to improve the prognostic and predictive indicators in non-small cell lung cancer (NSCLC). At present, the main focus is on genetic predictive markers while the prognostic value of the standard blood variables related to haematopoiesis has been subjected to relatively limited attention. To study the prognostic potential of haemoglobin (Hgb), platelet (Plt) and white blood cell (WBC) levels at time of diagnosis in NSCLC patients, 835 NSCLC patients, stage I-IV, who received radiotherapy with curative intention (> 50 Gy), were included in the study. WBC, Plt, Hgb, gender, age at diagnosis, stage, surgery and first-line chemotherapy were studied in relation to overall survival. For patients with Hgb < 110 g/L and Hgb a parts per thousand yen 110 g/L), the median survival was 11.2 and 14.5 months, respectively (p = 0.0032). For WBC > 9.0 x 10(9)/L and < 9.0 x 10(9)/L, the median survival was 11.6 and 15.4 months, respectively (p < 0.0001). For Plt > 350 x 10(9)/L and < 350 x 10(9)/L, the median survival was 11.2 and 14.9 months, respectively (p < 0.0001). The median survival in patients with pathological results in all three markers was half of that in patients with normal levels of all three markers (8.0 and 16.0 months, respectively (p < 0.0001). The level of the three studied haematological biomarkers corresponds significantly to outcome in NSCLC. These results indicate that standard haematological variables may be used as guidance for the clinician in the decision-making regarding treatment intensity and patient information. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/3379495
- author
- organization
- publishing date
- 2012
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Non-small cell lung cancer, Prognosis, Biomarker, Anaemia, Thrombocytosis, Leukocytosis
- in
- Medical Oncology
- volume
- 29
- issue
- 5
- pages
- 3176 - 3182
- publisher
- Humana Press
- external identifiers
-
- wos:000311513800027
- scopus:84880266943
- pmid:22565809
- ISSN
- 1559-131X
- DOI
- 10.1007/s12032-012-0247-3
- language
- English
- LU publication?
- yes
- id
- ee2be92d-a9ca-4856-9864-cc29aac5b40a (old id 3379495)
- date added to LUP
- 2016-04-01 13:23:47
- date last changed
- 2022-03-29 07:14:16
@article{ee2be92d-a9ca-4856-9864-cc29aac5b40a,
abstract = {{There is a need to improve the prognostic and predictive indicators in non-small cell lung cancer (NSCLC). At present, the main focus is on genetic predictive markers while the prognostic value of the standard blood variables related to haematopoiesis has been subjected to relatively limited attention. To study the prognostic potential of haemoglobin (Hgb), platelet (Plt) and white blood cell (WBC) levels at time of diagnosis in NSCLC patients, 835 NSCLC patients, stage I-IV, who received radiotherapy with curative intention (> 50 Gy), were included in the study. WBC, Plt, Hgb, gender, age at diagnosis, stage, surgery and first-line chemotherapy were studied in relation to overall survival. For patients with Hgb < 110 g/L and Hgb a parts per thousand yen 110 g/L), the median survival was 11.2 and 14.5 months, respectively (p = 0.0032). For WBC > 9.0 x 10(9)/L and < 9.0 x 10(9)/L, the median survival was 11.6 and 15.4 months, respectively (p < 0.0001). For Plt > 350 x 10(9)/L and < 350 x 10(9)/L, the median survival was 11.2 and 14.9 months, respectively (p < 0.0001). The median survival in patients with pathological results in all three markers was half of that in patients with normal levels of all three markers (8.0 and 16.0 months, respectively (p < 0.0001). The level of the three studied haematological biomarkers corresponds significantly to outcome in NSCLC. These results indicate that standard haematological variables may be used as guidance for the clinician in the decision-making regarding treatment intensity and patient information.}},
author = {{Holgersson, Georg and Sandelin, Martin and Hoye, Even and Bergstrom, Stefan and Henriksson, Roger and Ekman, Simon and Nyman, Jan and Helsing, Martin and Friesland, Signe and Holgersson, Margareta and Lundstrom, Kristina Lamberg and Janson, Christer and Birath, Elisabet and Morth, Charlotte and Blystad, Thomas and Ewers, Sven-Börje and Loden, Britta and Bergqvist, Michael}},
issn = {{1559-131X}},
keywords = {{Non-small cell lung cancer; Prognosis; Biomarker; Anaemia; Thrombocytosis; Leukocytosis}},
language = {{eng}},
number = {{5}},
pages = {{3176--3182}},
publisher = {{Humana Press}},
series = {{Medical Oncology}},
title = {{Swedish lung cancer radiation study group: the prognostic value of anaemia, thrombocytosis and leukocytosis at time of diagnosis in patients with non-small cell lung cancer}},
url = {{http://dx.doi.org/10.1007/s12032-012-0247-3}},
doi = {{10.1007/s12032-012-0247-3}},
volume = {{29}},
year = {{2012}},
}